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Abstract
Background: Methamphetamine (MA) use continues to be a major public health concern in many urban settings.
We sought to assess potential relationships between MA use and individual, social, and structural HIV vulnerabilities
among sexual minority (lesbian, gay, bisexual or transgendered) drug users.
Methods: Beginning in 2005 and ending in 2008, 2109 drug users were enroled into one of three cohort studies
in Vancouver, Canada. We analysed longitudinal data from all self-identified sexual minority participants (n = 248).
Logistic regression using generalized estimating equations (GEE) was used to examine the independent correlates
of MA use over time. All analyses were stratified by biological sex at birth.
Results: At baseline, 104 (7.5%) males and 144 (20.4%) females reported sexual minority status, among whom 64
(62.1%) and 58 (40.3%) reported MA use in the past six months, respectively. Compared to heterosexual
participants, sexual minority males (odds ratio [OR] = 3.74, p < 0.001) and females (OR = 1.80, p = 0.003) were
more likely to report recent MA use. In multivariate analysis, MA use among sexual minority males was associated
with younger age (adjusted odds ratio [AOR] = 0.93 per year older, p = 0.011), Aboriginal ancestry (AOR = 2.59, p
= 0.019), injection drug use (AOR = 3.98, p < 0.001), having a legal order or area restriction (i.e., “no-go zone”)
impact access to services or influence where drugs are used or purchased (AOR = 4.18, p = 0.008), unprotected
intercourse (AOR = 1.62, p = 0.048), and increased depressive symptoms (AOR = 1.67, p = 0.044). Among females,
MA use was associated with injection drug use (AOR = 2.49, p = 0.002), Downtown South residency (i.e., an area
known for drug use) (AOR = 1.60, p = 0.047), and unprotected intercourse with sex trade clients (AOR = 2.62,
p = 0.027).
Conclusions: Methamphetamine use was more prevalent among sexual minority males and females and was
associated with different sets of HIV risks and vulnerabilities. Our findings suggest that interventions addressing
MA-related harms may need to be informed by more nuanced understandings of the intersection between drug
use patterns, social and structural HIV vulnerabilities, and gender/sexual identities. In particular, MA-focused
prevention and treatment programs tailored to disenfranchised male and female sexual minority youth are
recommended.
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Like many other marginalised groups, lesbian, gay,
bisexual, and transgendered (LGBT) populations experi-
ence a range of health inequities and vulnerabilities
compared to the general population [1]. In addition to
the multiple health conditions that disproportionately
affect LGBT populations, sexual minorities also experi-
ence significant barriers to accessing appropriate care
and prevention services [2,3]. Due in part to the histori-
cal invisibility of LGBT persons and a reluctance among
some communities to consider sexual minorities as a
“legitimate” marginalised group, this population con-
tinues to be underrepresented in public health research
and practice [4].
A number of studies have demonstrated a high preva-
lence of substance use and dependence among sexual
minority groups [5,6]. For example, methamphetamine
(MA) use has been well studied among gay, bisexual,
and other men who have sex with men (MSM), particu-
larly in relation to increased sexual risk behaviour and
HIV transmission [7-9]. Although much less research
has been conducted among sexual minority women, sev-
eral cross sectional studies have demonstrated that les-
bian and bisexual-identified females report significantly
higher rates of MA use [10,11]. MA use among women
who inject drugs (IDU) has also been associated with
sexual- and injection-related HIV risk behaviour [12].
These studies and other research imply important gen-
der differences in the typologies of and adverse health
outcomes associated with MA use [13]; therefore, gen-
der-based analyses involving sexual minority populations
are needed to better inform effective public health
approaches and practice.
Although the individual and psychosocial factors that
drive HIV risk within the context of MA use are rela-
tively well understood [14-16], research has only begun
to elucidate how environmental and structural determi-
nants link MA use with increased HIV vulnerability
[17]. In order to most effectively reduce MA-related
exposure to HIV risks, several authors have called for
the investigation of personal, social, environmental, and
structural correlates of MA use and harms [17,18]. The
“risk environment” framework, which posits that factors
exogenous to the individual intersect to (re)-produce
HIV risk and other drug-related harms [19], provides
one such conceptual model to guide investigation of the
associations between MA use and HIV vulnerabilities
operating at various levels of influence.
Using data collected from three large ongoing pro-
spective cohort studies of drug users in Vancouver,
Canada, we sought to determine the prevalence of MA
use among sexual minority males and females. Further-
more, relying on a risk environment approach, we
assessed the relationships between MA use and a range
of individual, social, and structural HIV-related vulner-
abilities with the aim of indentifying through which
pathways MA use may exacerbate exposure to HIV risk.
Methods
Study Design
The At Risk Youth Study (ARYS), Vancouver Injection
Drug Users Study (VIDUS) and AIDS Care Cohort to
Evaluate Access to Survival Services (ACCESS) are open
prospective cohorts of drug users in Vancouver, Canada.
These studies comprise a larger program of research
focused on the study of the initiation and natural history
of injection drug use, and are administered by one
research centre (i.e., the British Columbia Centre for
Excellence in HIV/AIDS). The risk environment frame-
work is utilized as the theoretical foundation from
which to examine how a variety of factors within social,
physical, and political space interact to (re)-produce
HIV and drug-related harm [19]. Recruitment proce-
dures for the three studies are similar, with the primary
modes of enrolment being self-referral, word of mouth,
and street outreach. Participants of all studies must have
resided in the greater Vancouver region and provided
informed consent to be eligible. Each study also had
specific eligibility criteria that are detailed briefly here.
ARYS consists of drug-using street-involved youth; thus,
eligibility criteria included being between the age of 14
and 26 and the use of illicit drugs other than or in addi-
tion to marijuana in the past 30 days. VIDUS is a study
of HIV-negative IDU in which all participants must
have injected an illicit drug in the past 6 months to be
eligible for inclusion. ACCESS is a cohort of HIV-posi-
tive individuals, who, similar to those in ARYS, must
have recently used an illicit drug other than or in addi-
tion to marijuana. Detailed sampling and recruitment
procedures for these three cohorts have been described
elsewhere [20-22]. In this analysis, we combined data
from all three studies to achieve a sample size with suf-
ficient power to examine MA use among the sub-sample
of participants who identified as a sexual minority.
While combining data from studies with different inclu-
sion criteria may present some challenges, we note that
all studies rely on harmonized recruitment and data col-
lection tools. Furthermore, combining the datasets per-
mitted an examination of MA use patterns across a
diverse spectrum of drug users (e.g., street-involved
youth, older IDU) in our setting.
At baseline and semi-annually, participants completed
a lengthy interviewer-administered questionnaire. Socio-
demographic data, as well as information pertaining to
drug use patterns, risk behaviours, and health care utili-
sation are collected. The survey for each study consists
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gation and analysis of data from all enrolled participants.
Nurses collected blood specimens for HIV and hepatitis
C serology and also provided basic medical care and
referrals to appropriate health care services. Participants
received $20 for each study visit. All studies have been
approved by the University of British Columbia/Provi-
dence Health Care Research Ethics Board.
Study Sample
Data from each cohort used in this analysis was col-
lected during the same time frame; thus, all individuals
were observed over the same follow-up period. All parti-
cipants who completed a baseline survey between Sep-
tember 2005 and May 2008 were eligible for inclusion.
At baseline, participants were asked to identify their bio-
logical sex at birth and their current sexual orientation.
“Sexual minority status” was defined as answering affir-
matively to one of: gay, lesbian, bisexual, transsexual,
transgendered, or other. Participants who refused to
report their sex at birth or current sexual and gender
identity were excluded from this analysis.
Study Hypotheses
The primary hypothesis guiding this analysis was based
on the risk environment framework and a careful assess-
ment of prior literature investigating the relationship
between MA use and HIV risk behaviour. We hypothe-
sized that MA use among sexual minority drug users
would be associated with differing exposure to indivi-
dual, social, and structural HIV vulnerabilities. In an
effort to build on previous studies [16,23,24], we sought
not only to examine individual-level HIV risk behaviour
but also contextual factors including homelessness,
neighbourhood of residence, the consumption of drugs
in public, and the regulation of these spaces by law
enforcement personnel. We also considered the relation-
ship between MA use and physical violence and depres-
sion, which have been identified as independent risk
factors for HIV infection [9,25]. Finally, we hypothesized
that the relationship between MA use and these factors
would differ significantly between sexual minority males
and females.
Variables of Interest
The primary outcome of interest was ascertained by
examining responses to the questions, “In the last six
months, did you use non-injection crystal methampheta-
mine?” and “In the last six months, did you inject crystal
methamphetamine?” Participants who responded “yes”
to either or both questions were defined as crystal
methamphetamine (MA) users in all subsequent ana-
lyses. We also determined the proportion of partici-
pants reporting daily or greater use of injection or
non-injection MA use in the past 6 months, respec-
tively. All variables examined in this study, including
the outcomes and independent variables of interest,
were assessed consistently and equivalently across all
three studies.
Based on prior literature examining MA use among
marginalised populations [12,26-29], we assessed as
explanatory variables a broad set of sociodemographic
characteristics, drug use variables, sexual activities, mar-
kers of violence and depression, and contextual factors.
These variables were also chosen to represent both
“micro”- (i.e., the immediate social environment of drug
use) and “macro"- (i.e., the societal, economic, and legal
context that structure drug use and harm) levels articu-
lated by the risk environment framework [19]. Sociode-
mographic characteristics examined included age (per
year older), Aboriginal ancestry (yes versus no), current
relationship status (single/dating versus married/regular
partner), and baseline HIV status (positive versus nega-
tive). All other variables (unless otherwise indicated)
referred to behaviours or activities in the past 6 months
since the date of the interview. Drug use variables
assessed included other stimulant use (i.e., non-injection
cocaine use and crack use, respectively), any injection
drug use, experiencing a non-fatal overdose, and binge
drug use. As defined previously [30], the latter was oper-
ationalised as the self-reported use of drugs more often
than usual. We also examined the following sexual
activities: number of casual or regular partners exclud-
ing those in the context of sex work (>1 versus ≤1); any
vaginal or anal unprotected intercourse with casual or
regular partners (yes versus no); and sex trade work,
defined as a categorical variable with “no” as the refer-
ence level and consistent condom use with all clients
and any unprotected intercourse with clients as the sec-
ond and third levels, respectively. We ascertained invol-
vement in (i.e., committing) and exposure to (i.e.,
experiencing) physical violence (yes versus no). We also
used the Center for Epidemiologic Studies Depression
Scale (CES-D) with a cut-off of ≥16 to measure the level
of depressive symptomatology among participants [31].
Finally, contextual factors examined included: residency
in the Downtown South (DTS), an area known as a
mixed business and entertain m e n td i s t r i c tt h a ti sa l s o
inhabited by a large street youth population [32]; home-
lessness (yes versus no); having a warrant or area
restriction (i.e., “no go zone”) impact access to services
or influence where drugs are consumed or purchased
(yes versus no); and using drugs in public spaces (>75%
of the time versus ≤75% of the time). Warrants and area
restrictions are legal orders to restrict access to certain
areas of the city, and are commonly issued by law enfor-
cement personnel in an attempt to disrupt crime and
reduce street level disorder [33].
Marshall et al. BMC Public Health 2011, 11:20
http://www.biomedcentral.com/1471-2458/11/20
Page 3 of 10Statistical Analysis
As a preliminary analysis, we compared the baseline
sociodemographic characteristics and MA use patterns
between heterosexual and sexual minority participants,
stratified by biological sex at birth. The Pearson chi-
square test was used to compare categorical variables
and the Wilcoxon rank sum test was used for continu-
ous variables. We then identified the longitudinal corre-
lates of MA use by using generalized estimating
equations (GEE) with a logit link for binary outcomes.
GEE were appropriate for this analysis since the factors
associated with recent MA use over the baseline and
four follow-up periods were serial (i.e., time-dependent)
variables. GEE account for the correlation between
repeated measures for each subject; thus, valid estimates
of association and standard errors are obtained [34].
Since GEE models incorporate periods during which
participants report engaging and not engaging in the
outcome, data from all baseline and follow-up interviews
were used in this analysis.
Since a primary objective of this study was to deter-
mine whether the correlates of MA use differed between
males and females, we stratified the analyses by biologi-
cal sex at birth and constructed two multivariate mod-
els. We applied a modified backward stepwise procedure
to select covariates based on two criteria: the Akaike
information criterion (AIC) and type-III p-values [35].
Lower AIC values indicate a better overall fit and lower
p-values indicate higher variable significance. Starting
with a full model containing all variables that were sig-
nificant in bivariate analyses at p < 0.10, covariates were
removed sequentially in order of decreasing p-values. To
compensate for potential variations in recruitment and
selection procedures between studies, we also adjusted
each model for cohort of enrolment. At each step, the
p-values of each variable and the overall AIC were
recorded, with the final model having the lowest AIC.
Statistical analysis was conducted using SAS version
9.1.3 (SAS Institute Inc., Cary, North Carolina, USA)
and all p-values are two-sided.
Results
Sample Characteristics
Between September 2005 and May 2008, 2109 unique
individuals were enrolled into the ARYS, VIDUS or
ACCESS cohorts. A total of 14 (0.7%) refused to report
their sex at birth or current sexual/gender identity and
were thus excluded for the analysis. Of the 2095 eligible
participants, 1389 (66.3%) were male and 706 (33.7%)
were female. Among all participants, the median age at
baseline was 37.0 (IQR: 24.7 - 45.4) and 641 (30.6%)
were of Aboriginal ancestry. The majority identified
their sexual or gender identity as heterosexual (n =
1847, 88.2%), followed by bisexual (n = 168, 8.0%), gay
(n = 43, 2.1%), lesbian (n =9 ,0 . 4 % ) ,a n dt r a n s s e x u a l ,
transgendered, or other (n = 28, 1.3%). Among those
who reported their biological sex at birth as female, 144
(20.4%) identified as a sexual minority compared to only
7.5% (n = 104) of biological males.
Baseline Methamphetamine Use
Sociodemographic characteristics and methamphetamine
use patterns for males and females stratified by sexual
orientation are displayed in Table 1. At baseline, sexual
minority males were more likely to be younger (median
=3 3v e r s u s3 9 ,p = 0.001), HIV positive (40.4% versus
21.2%, p < 0.001), and of Aboriginal ancestry (40.4% ver-
sus 23.7%, p < 0.001). In contrast, sexual minority
females were less likely to be of Aboriginal ancestry
(33.3% versus 43.9%, p = 0.023). Among both males and
females, sexual minority participants were significantly
more likely to report injection and non-injection MA
use in the past 6 months (Table 1). Notably, over half
(62.1%) of sexual minority males reported recently using
MA, and a significant proportion (16.7%) reported
injecting MA at least daily. Approximately half (n = 142,
57.3%) of sexual minority participants reported having
used MA for at least a year since the date of the base-
line interview.
Longitudinal Correlates of Methamphetamine Use
In Table 2, we report the results of the longitudinal ana-
lysis examining the factors associated with MA use
among sexual minority males. Bivariate analyses indi-
cated that male MA users were more likely to experi-
ence a variety of sexual HIV risks and vulnerabilities,
including for example multiple recent sex partners
(odds ratio [OR] = 1.91, p = 0.002), unprotected inter-
course (OR = 1.86, p = 0.004), and unprotected inter-
course in the context of sex work (OR = 3.25, p =
0.005). MA using men were also more likely to report
injection drug use (OR = 2.31, p = 0.004), experience
physical violence (OR = 1.76, p =0 . 0 0 4 ) ,c o m m i tp h y s i -
cal violence (OR = 1.90, p =0 . 0 2 5 )a n de x h i b i td e p r e s -
sive symptoms (OR = 1.79, p = 0.010). In multivariate
analysis, independent correlates of MA use among sex-
ual minority males included: younger age (adjusted odds
ratio [AOR] = 0.93, p = 0.011), Aboriginal ancestry
(AOR = 2.59, p = 0.019), injection drug use (adjusted
odds ratio [AOR] = 3.98, p < 0.001), unprotected sexual
intercourse (AOR = 1.62, p = 0.048), increased depres-
sive symptoms (AOR = 1.67, p =0 . 0 4 4 ) ,a n dh a v i n ga n
area restriction impact access to services or influence
where drugs are used or purchased (AOR = 4.18, p =
0.008).
Increased sexual HIV vulnerabilities were also
observed among MA-using sexual minority females
(Table 3). For example, females reporting recent MA
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sex partners (OR = 1.55, p = 0.029). Several associations
that were observed among MA-using males were also
significant among females. For example, female MA
users were younger (OR = 0.95, p = 0.005), more likely
to inject drugs (OR = 1.68, p = 0.011), and reported ele-
vated rates of unprotected intercourse in the context of
sex work (OR = 3.27, p = 0.001). In contrast, MA-using
females were less likely to be of Aboriginal ancestry (OR
= 0.41, p = 0.012).
In a multivariate analysis, several unique correlates of
MA use emerged among sexual minority females. In
contrast to males, MA-using females were more likely
to reside in the Downtown South neighbourhood (AOR
=1 . 6 0 ,p = 0.047). Furthermore, MA use among sexual
minority females was independently associated with
unprotected intercourse with sex trade clients (AOR =
2.62, p = 0.027). Similar to males, MA-using females
were more likely to report injection drug use (AOR =
2.49, p = 0.002).
Table 1 Baseline sociodemographic characteristics and methamphetamine use patterns among ARYS, VIDUS, and
ACCESS participants, stratified by biological sex at birth and self-identified sexual orientation (n, % unless otherwise
indicated)
Male (N = 1389) Female (N = 706)
Characteristic Sexual Minority*
(n = 104)
Heterosexual
(n = 1285)
OR
(95%CI)
p-
value
Sexual Minority*
(n = 144)
Heterosexual
(n = 562)
OR (95%
CI)
p-
value
Age (median, IQR) 33 (24 - 42) 39 (25 - 47) 0.97 (0.95 -
0.99)
0.001 31 (23 - 41) 35 (24 - 44) 0.98 (0.97 -
1.00)
0.053
Aboriginal ancestry
Yes 42 (40.4) 305 (23.7) 2.18 (1.44 -
3.29)
<0.001 48 (33.3) 246 (43.9) 0.64 (0.44 -
0.94)
0.023
No 62 (59.6) 980 (76.3) 96 (66.7) 315 (56.2)
Relationship status
Single/dating 73 (70.2) 927 (72.4) 0.90 (0.58 -
1.39)
0.634 90 (62.5) 307 (55.4) 1.34 (0.92 -
1.95)
0.127
Married/regular
partner
31 (29.8) 354 (27.6) 54 (37.5) 247 (44.6)
HIV status
Positive 42 (40.4) 272 (21.2) 2.52 (1.67 -
3.82)
<0.001 41 (28.5) 159 (28.3) 1.01 (0.67 -
1.51)
0.966
Negative 62 (59.6) 1013 (78.8) 103 (71.5) 403 (71.7)
Any meth use
†
Yes 64 (62.1) 388 (30.5) 3.74 (2.47 -
5.67)
<0.001 58 (40.3) 150 (27.2) 1.80 (1.23 -
2.64)
0.003
No 39 (37.9) 884 (69.5) 86 (59.7) 401 (72.8)
Any non-injection
meth use
†
Yes 38 (36.5) 223 (17.5) 2.71 (1.78 -
4.15)
<0.001 36 (25.0) 89 (16.0) 1.75 (1.12 -
2.71)
0.013
No 66 (63.5) 1050 (82.5) 108 (75.0) 466 (84.0)
Daily non-injection
meth use
†
Yes 11 (10.6) 39 (3.1) 3.72 (1.84 -
7.50)
<0.001 8 (5.6) 20 (3.7) 1.56 (0.67 -
3.62)
0.296
No 93 (89.4) 1226 (96.9) 135 (94.4) 527 (96.3)
Any injection meth
use
†
Yes 43 (41.4) 262 (20.4) 2.75 (1.82 -
4.15)
<0.001 39 (27.1) 100 (18.0) 1.69 (1.10 -
2.59)
0.016
No 61 (58.6) 1021 (79.6) 105 (72.9) 455 (82.0)
Daily injection meth
use
†
Yes 17 (16.7) 45 (3.5) 5.45 (3.00 -
9.95)
<0.001 9 (6.4) 16 (2.9) 2.27 (0.98 -
5.24)
0.066
No 85 (83.3) 1229 (96.5) 132 (93.6) 532 (97.1)
Notes: * “sexual minority” refers to lesbian, gay, bisexual, transgendered, transsexual, or other orientation; † refers to activities in the past 6 months.
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In the current study, we observed a high prevalence of
MA use among sexual minority males and females in
comparison to heterosexual participants. We also found
that, consistent with the risk environment framework,
MA use was associated with an array of individual,
social, and contextual HIV-related risks and vulnerabil-
ities among sexual minority drug users.
Although some correlates of MA use (e.g., younger
age and injection drug use) were significant for both
sexes, several important differences were observed. For
example, unprotected intercourse involving regular or
casual partners was more common among males who
reported using methamphetamine, while unprotected
intercourse in the context of sex work was associated
with MA use among females. Furthermore, only MA-
using males were more likely to experience depressive
symptoms and report having area restrictions (i.e., “no
go” zones) impact access to services of influence where
drugs are used or purchased. These findings may be due
to the fact that sexual minority males reported heavier
MA use patterns compared to females, and thus may be
more likely to experience individual (i.e., depressive
symptoms) and contextual (i.e., exposure to law enforce-
ment) MA-related sequelae. Finally, Aboriginal ancestry
was positively associated with MA use among males but
inversely associated with MA use among females.
Consistent with other studies [7,8,36], MA use was
linked with unprotected intercourse among sexual min-
ority men. Although we were unable to ascertain the
context in which instances of unprotected intercourse
occurred, we point to other research indicating that
homeless sexual minority males frequently experience
sexual victimization and abuse from partners [37].
Although more research is required to fully elucidate
casual mechanisms, we hypothesize that the relationship
between sexual risk and MA use observed among this
sample of street-involved sexual minority men is less a
function of desire to enhance sex but is in fact a marker
of increased vulnerability within sexual relationships.
Table 2 Longitudinal analysis of factors associated with crystal methamphetamine use† among sexual minority* males
(n = 104)
Bivariate Multivariate
Characteristic Odds Ratio 95% CI p-value Adjusted Odds Ratio 95% CI p-value
Sociodemographic Characteristics
Age (per year) 0.92 0.89 - 0.96 <0.001 0.93 0.88 - 0.98 0.011
Aboriginal ancestry (yes vs. no) 2.37 1.17 - 4.79 0.016 2.59 1.17 - 5.77 0.019
Relationship status (single/dating vs. married/partner) 0.96 0.65 - 1.42 0.842
HIV Status (positive vs. negative) 0.50 0.24 - 1.00 0.051
Drug Use
Non-injection cocaine use
† (yes vs. no) 2.44 1.09 - 5.44 0.029
Crack use
† (yes vs. no) 1.47 0.89 - 2.43 0.133
Any injection drug use
† (yes vs. no) 2.31 1.30 - 4.11 0.004 3.98 1.85 - 8.57 <0.001
Overdose
† (yes vs. no) 1.52 0.83 - 2.77 0.172
Binge drug use
† (yes vs. no) 1.50 0.90 - 2.50 0.118
Sexual Activities
Number of sex partners
† (>1 vs. ≤1) 1.91 1.28 - 2.86 0.002
Unprotected intercourse
† (yes vs. no) 1.86 1.22 - 2.84 0.004 1.62 1.01 - 2.60 0.048
Sex trade work
† (ref = no sex trade work)
Consistent condom use with clients
† (yes vs. ref) 2.79 1.62 - 4.82 <0.001
Any unprotected sex with clients
† (yes vs. ref) 3.25 1.44 - 7.37 0.005
Violence & Depression
Experience physical violence
† (yes vs. no) 1.76 1.20 - 2.59 0.004 1.47 0.93 - 2.32 0.100
Commit physical violence
† (yes vs. no) 1.90 1.09 - 3.31 0.025
Clinical depression (CES-D
‡ ≥16 vs. <16) 1.79 1.15 - 2.79 0.010 1.67 1.01 - 2.76 0.044
Contextual Factors
Downtown South residency (yes vs. no) 1.45 0.90 - 2.34 0.124
Homeless
† (yes vs. no) 1.76 1.00 - 3.09 0.050
Area restrictions influence drug use (yes vs. no) 4.02 0.87 - 18.54 0.075 4.18 1.46 - 11.95 0.008
Use drugs in public
† (>75% vs. ≤75% of the time) 1.53 0.96 - 2.43 0.073
Notes: model adjusted for cohort of recruitment; * “sexual minority” refers to lesbian, gay, bisexual, transgendered, transsexual, or other orientation; † refers to
activities in the past 6 months; ‡ CES-D refers to the Center for Epidemiologic Studies Depression Scale.
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ciation between MA use and experiencing physical vio-
lence observed among males in this study.
In multivariate analysis, among the subsample of
females engaging in sex work, MA use was associated
with unprotected intercourse with clients. This finding
can be situated within a growing literature demonstrat-
ing how social and structural inequities hinder the indi-
vidual agency of drug-using survival sex workers to
practice HIV prevention and harm reduction with cli-
ents [38]. In a recent study of female sex workers (FSW)
in Vancouver, Canada, Shannon et al. [39] demonstrated
that MA use is associated with living and working in
marginalised public spaces (e.g., industrial areas). These
areas have been shown in previous research to be set-
tings of increased risk of violence and pressure from cli-
ents to engage in unprotected sex [40]. Our results
support this work and indicate that MA use may aug-
ment the adverse impact of social-structural factors in
the production of HIV risk among sexual minority
women involved in survival sex work.
The strongest correlate of MA use among sexual min-
ority men was reporting that a warrant or area restric-
tion impacted access to services or influenced where
drugs are consumed or purchased. The socio-legal regu-
lation of public space and its negative impact on the
health of homeless people and street-level drug users
has been described previously [41]. Recent work also
suggests that the displacement of street-involved young
people using warrants or area restrictions exacerbates
stigma and increases sexual vulnerability and HIV risk
[42]. Our findings suggest that having one’s movements
restricted may also encourage transitions in drug use
(including initiation of MA use), due perhaps to the
forced removal of drug users from normative environ-
ments and social networks. It is also possible that MA
users are at an increased risk of incarceration and other
interactions with the legal system, and are thus more
Table 3 Longitudinal analysis of factors associated with crystal methamphetamine use† among sexual minority*
females (n = 144)
Bivariate Multivariate
Characteristic Odds Ratio 95% CI p-value Adjusted Odds Ratio 95% CI p-value
Sociodemographic Characteristics
Age (per year) 0.95 0.92 - 0.99 0.005
Aboriginal ancestry (yes vs. no) 0.41 0.21 - 0.82 0.012 0.55 0.25 - 1.21 0.137
Relationship (single/dating vs. married/partner) 1.07 0.76 - 1.49 0.708
HIV Status (positive vs. negative) 0.62 0.90 - 1.30 0.209
Drug Use
Non-injection cocaine use
† (yes vs. no) 1.79 1.06 - 3.04 0.030 1.66 0.94 - 2.92 0.079
Crack use
† (yes vs. no) 0.95 0.71 - 1.27 0.730
Any injection drug use
† (yes vs. no) 1.68 1.13 - 2.50 0.011 2.49 1.42 - 4.39 0.002
Overdose
† (yes vs. no) 1.47 0.90 - 2.41 0.126
Binge drug use
† (yes vs. no) 1.18 0.77 - 1.81 0.452
Sexual Activities
Number of sex partners
† (>1 vs. ≤1) 1.55 1.05 - 2.30 0.029
Unprotected intercourse
† (yes vs. no) 0.97 0.65 - 1.45 0.897
Sex trade work
† (ref = no sex trade work)
Consistent condom use with clients
† (yes vs. ref) 1.30 0.88 - 1.93 0.189 1.16 0.72 - 1.87 0.543
Any unprotected sex with clients
† (yes vs. ref) 3.27 1.60 - 6.68 0.001 2.62 1.12 - 6.14 0.027
Violence & Depression
Experience physical violence
† (yes vs. no) 1.24 0.88 - 1.75 0.210
Commit physical violence
† (yes vs. no) 1.12 0.81 - 1.54 0.499
Clinical depression (CES-D
‡ ≥16 vs. <16) 0.85 0.66 - 1.09 0.204
Contextual Factors
Downtown South residency (yes vs. no) 1.45 1.00 - 2.10 0.053 1.60 1.01 - 2.54 0.047
Homeless
† (yes vs. no) 1.19 0.86 - 1.64 0.299
Area restrictions influence drug use (yes vs. no) 0.59 0.28 - 1.23 0.160
Use drugs in public
† (>75% vs. ≤75% of the time) 1.18 0.77 - 1.81 0.446
Notes: model adjusted for cohort of recruitment; * “sexual minority” refers to lesbian, gay, bisexual, transgendered, transsexual, or other orientation; † refers to
activities in the past 6 months; ‡ CES-D refers to the Center for Epidemiologic Studies Depression Scale.
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and area restrictions. This form of marginalisation (pro-
duced by policies and practices meant to reduce expo-
sure to street-level drug use and violence) is one
example of a population-level intervention that may
exacerbate inequity and worsen the health of vulnerable
groups [43].
These findings also support the urgent need for
increased resources and programming directed towards
LGBT people who use methamphetamine. In order to
inform more effective interventions to reduce the harms
associated with MA, researchers must clearly articulate
how social/structural processes impact the health of sex-
ual minorities. Once clearly identified, these factors can
then be the target of broad sets of evidence-based inter-
ventions to reduce health inequities and improve overall
health. For example, changes in government policy
along with community mobilization and solidarity pro-
grams have been shown to be highly successful at redu-
cing HIV risk among survival sex workers [44].
Programs that support capacity-building in marginalised
communities have also been shown to reduce health
inequity and improve health outcomes [45]. Although
further research is required to elucidate the potential
impact of specific enforcement practices (e.g., area
restrictions) on MA use and related harms, improved
coordination between policing and public health initia-
tives may represent another opportunity to prevent the
(un)-intended consequences of public policies meant to
reduce crime and street disorder [46]. Finally, additional
research is required to identify specific programmatic
needs of subpopulations within sexual minority commu-
nities, including for example transgendered youth.
To complement structural interventions, some beha-
vioural approaches (e.g., cognitive behavioural therapy)
offer promise [47]. For example, LGBT-specific sub-
stance abuse treatment programs have been found to
reduce engagement in high-risk sex among drug-using
gay men [48]. Harm reduction programs, particularly
those offering tailored services for MA users, are effec-
tive and well received by clients [49]. Finally, given the
associations between Aboriginal ancestry, sexual orienta-
tion, and MA use observed in this study, methampheta-
mine-specific programming should carefully identify the
manner in which cultural and sexual identities shape
drug use and HIV risk within specific contexts and
settings.
This study has a number of limitations that should be
noted. The ARYS, VIDUS, and ACCESS cohorts are not
random samples of the eligible population; thus, findings
may not necessarily be generalizable to other urban
areas in which MA use is prevalent. The small sample
sizes may have resulted in insufficient power to detect
true associations, particularly after adjustment for con-
founding. Furthermore, data from three studies with dif-
ferent inclusion criteria were combined and analysed,
which may have resulted in cohort or selection effects.
To mitigate the potential impact of these biases, all sam-
pling and data collection procedures were harmonized,
and all multivariate models were adjusted for cohort of
recruitment. We note that all behaviours ascertained in
this study were self-reported, and we were unable to
confirm MA use with urine samples or other measures.
We also recognize that our primary analysis was
restricted to individuals who self-identified as a sexual
minority; therefore, heterosexual-identified individuals
who engaged in same-sex activity were excluded. We
chose not to rely on behavioural eligibility criteria (e.g.,
MSM), as we feel, as do others [50], that ignoring sexual
identity in HIV prevention efforts obscures the social
dimensions of sexuality that are critical for the develop-
ment of effective and culturally relevant public health
interventions. However, we note that public health
efforts should be made to provide appropriate services
for non-LGBT identifying MSM/WSW, including pro-
grams that explicitly acknowledge and accept diverse
sexual experiences and identities [51]. We were unable
to ascertain motivations for MA use, which if examined
may have accounted some of the observed differences in
the characteristics and consequences of MA use
between male and female participants in this study.
Finally, although our data are longitudinal, we do not
wish to imply that this analysis provides thorough
insight into the causal pathways linking MA use and
HIV risk with broader social and structural inequities.
Conclusion
We have demonstrated in a longitudinal data set a high
prevalence of MA use among a cohort of street-involved
sexual minority drug users. To our knowledge, this is
the first study to extend the risk environment approach
as a theoretical foundation from which to understand
the contexts of risk associated with MA use among
LGBT populations. Consistent with the risk environ-
ment framework, MA use was associated with distinct
sets of individual, social, and structural HIV risks and
vulnerabilities among women and men, respectively;
therefore, comprehensive interventions that involve sec-
tors outside of health (e.g., housing, law enforcement),
in addition to drug-specific approaches tailored to
LGBT populations, are required to reduce HIV vulner-
ability and MA-related harms. Finally, researchers and
public health practitioners must identify multi-sector
population-level interventions that do not exacerbate
inequity but successfully mitigate health inequities
among vulnerable populations.
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